• KOLs Community
    • Heart
    • Heart Failure
    • Junbo Ge
    • Junbo Ge

      Junbo Ge

      Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China; Institute of Biomedical Science, Fudan ...



      KOL Resume for Junbo Ge


      Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China; Institute of Biomedical Science, Fudan University, Shanghai, China; NHC Key Laboratory of Viral Heart Diseases, Shanghai, China; Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, China. Electronic address:

      National Clinical Research Center for Interventional Medicine, Shanghai, China.

      Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China

      for the CCC-ACS Investigators


      Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Shanghai, PR China

      for the STABILITY Investigators


      World Heart Federation, Rue de Malatrex 32, 1201 Geneva, CH

      College of Cardiovascular Physicians, Chinese Medical Association, Shanghai 200032, China.

      Shanghai Institute of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China

      Zhongshan Hospital, Fudan University.


      Shanghai Institute of Cardiovascular Diseases, China (J.G.).


      From the Department of Cardiology, Peking University First Hospital, Beijing, China (F.F., J.L., Y.Z., Y.H.); Department of Neurology, Xijing Hospital, the Fourth Military Medical University, Xi'an, China (Z.Y., G.Z.); National Clinical Research Center for Kidney Disease; State Key Laboratory for Organ Failure Research; Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China (X.Q., Y.L., F.H., X.X.); Institute for Biomedicine, Anhui Medical University, Hefei, China (X.Q., T.Y.); Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital (M.J., J.G.), and Institutes of Biomedical Sciences (M.J., J.G.), Fudan University, Shanghai, China; Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, China (M.Z., X.Y.); Department of Cardiology, Second Affiliated Hospital, Nanchang University, China (H.B., X.C.); Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (D.G.); Department of Epidemiology, Capital Medical University Beijing Anzhen Hospital-Beijing Institute of Heart, Lung & Blood Vessel Diseases, China (D.Z.); Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, The Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine, China (J.W.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S.); Department of Cardiology, Chinese People's Liberation Army General Hospital, Beijing, China (Y.C.); Centers for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA (H.W.); Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (Xiaobin Wang); Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy (G.P.); Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy (G.P.); and Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China (Xian Wang).

      200032 复旦大学附属中山医院心内科 上海市心血管病研究所


      From the National Clinical Research Study Center for Kidney Disease, State Key Laboratory for Organ Failure Research, Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y.S., W.Z., C.Z., X.Q., F.F.H., B.W., X.X.); Department of Cardiology, Peking University First Hospital, Beijing, China (B.X., R.X., T.F., F.F., Y.Z., J.L., Y.H.); River Hill High School, Clarksville, MD (B.X., R.X., R.T., E.F., W.T.); Renmin University Affiliated High School of China, Beijing, China (T.F.); Shenzhen College of International Education, Guangdong, China (W.Z.); Institute for Biomedicine, Anhui Medical University, Hefei, China (T.Y., G.T.); Department of Cardiology, the Second Affiliated Hospital of Nanchang University, Jiangxi, China (H.B., X.C.); Department of Cardiology (Y.C.) and Department of Geriatric Cardiology (X.L.), General Hospital of People's Liberation Army, Beijing, China; Department of Cardiology, Xiangya Hospital, Central South University, Changsha, China (T.Y.); Department of Cardiology, Peking University People's Hospital, Beijing, China (N.S.); Department of Cardiology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, China (L.Z.); and Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital (J.G.) and Department of Neurology, Huashan Hospital (Q.D.), Fudan University, Shanghai, China.




      Zhoungshan Hospital, Fudan University Shanghai China




      Junbo Ge: Influence Statistics

      Sample of concepts for which Junbo Ge is among the top experts in the world.
      Concept World rank
      reattempted cto #1
      reattempted chronic #1
      reattempted #2
      mural coronary artery #2
      mural coronary #2
      diabetes primary outcome #3
      valve venus #3
      venus valve #5
      current status hypertension #5
      complications icus #6
      native rvot #7
      bapwv hypertension #7
      dapt ischemic outcomes #8
      bleeding 1month dapt #8
      dapt xience 90 #8
      dapt hbr patients #8
      bleeding 12 months #8
      cardiovascular dapagliflozin #8
      3month dapt xience #8


      Prominent publications by Junbo Ge

      KOL-Index: 22875

      BACKGROUND: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor.

      METHODS: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a ...

      Known for Coronary Artery | Ticagrelor Patients | Previous Pci | Cardiovascular Death | Myocardial Infarction
      KOL-Index: 21450

      BACKGROUND: Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease.

      METHODS: In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable ...

      Known for Coronary Artery | Rivaroxaban Aspirin | Major Bleeding | Myocardial Infarction | Combination Factor
      KOL-Index: 20808

      BACKGROUND: Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.

      METHODS: This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous ...

      Known for Rivaroxaban Aspirin | Carotid Artery | Major Bleeding | Myocardial Infarction | Cardiovascular Death
      KOL-Index: 18485

      Importance: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.

      Objective: To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.

      Design, Setting, and Participants: Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York ...

      Known for Dapagliflozin Patients | Cardiovascular Death | Heart Failure | Hazard Ratio | Exploratory Analysis
      KOL-Index: 18000

      BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore ...

      Known for Odyssey Outcomes | Coronary Syndrome | Patients Alirocumab | Controlled Trial | Primary Endpoint
      KOL-Index: 17308

      BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.

      METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ...

      Known for Heart Failure | Neprilysin Inhibition | Patients Sacubitril Valsartan | Death Cardiovascular | Nyha Class
      KOL-Index: 16409

      BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.

      METHODS: In this phase 3, placebo-controlled trial, we randomly assigned 4744 ...

      Known for Heart Failure | Hazard Ratio | Diabetes Patients | Ejection Fraction | Dapagliflozin Placebo
      KOL-Index: 15356

      BACKGROUND: Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men.

      METHODS: In a prespecified subgroup analysis, we examined outcomes according to sex in the PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction), ...

      Known for Heart Failure | Preserved Ejection Fraction | Women Compared | Sacubitril Valsartan | Prospective Comparison
      KOL-Index: 13558

      Recently, it was demonstrated that one allele (825T) of the gene encoding the G protein beta3 subunit (GNB3) is associated with hypertension in Germans. This study investigates a possible association with obesity in young male Germans, Chinese, and black South Africans with low, intermediate, and high 825T allele frequencies, respectively. In each of these three distinct cohorts, the 825T allele frequency was increased significantly in overweight (body mass index [BMI] > or =25 kg/m2) ...

      Known for 825t Allele | Protein Beta3 Subunit | Black African | Association Obesity | Continental Ancestry
      KOL-Index: 13139

      BACKGROUND: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality.

      METHODS AND RESULTS: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 ...

      Known for Heart Failure | Baseline Characteristics | Patients Hfpef | Preserved Ejection | Hf Trial
      KOL-Index: 12025

      Pulse wave velocity (PWV) has been shown to influence the effects of antihypertensive drugs in the prevention of cardiovascular diseases. Data are limited on whether PWV is an independent predictor of stroke above and beyond hypertension control. This longitudinal analysis examined the independent and joint effect of brachial-ankle PWV (baPWV) with hypertension control on the risk of first stroke. This report included 3310 hypertensive adults, a subset of the China Stroke Primary ...

      Known for Hypertensive Adults | Bapwv Stroke | Pulse Wave | Hazard Ratio | Pressure Control
      KOL-Index: 11851

      BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown.

      DESIGN AND METHODS: The Dapagliflozin And Prevention of ...

      Known for Patients Heart Failure | Ejection Fraction | Transporter 2 | Cardiovascular Death | Inhibitor Dapagliflozin
      KOL-Index: 11398

      We aimed to investigate the relationship of time-averaged on-treatment systolic blood pressure (SBP) with the risk of first stroke in the CSPPT (China Stroke Primary Prevention Trial). A post hoc analysis was conducted using data from 17 720 hypertensive adults without cardiovascular disease, diabetes mellitus, and renal function decline from the CSPPT, a randomized double-blind controlled trial. The primary outcome was first stroke. Over a median follow-up duration of 4.5 years, the ...

      Known for Blood Pressure | Primary Prevention | Risk Stroke | Mm Hg | Hazard Ratio
      KOL-Index: 8597

      BACKGROUND: Intracoronary ultrasound (ICUS) is increasingly used in clinical practice to study the natural history of coronary artery disease and to assess the effects of intracoronary, catheter-based interventions. However, the risk associated with the procedure is not well documented.

      METHODS AND RESULTS: ICUS studies performed in 28 centers were retrospectively included; these centers agreed to contribute to the study among a total of 60 centers initially invited. Among the 2207 ICUS ...

      Known for Intracoronary Ultrasound | Complications Icus | Acute Coronary | Patients 2 | Myocardial Infarction
      KOL-Index: 8377

      OBJECTIVES: The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).

      BACKGROUND: Current-generation drug-eluting stents are preferred over bare-metal stents for HBR patients, but their optimal DAPT management remains unknown.

      METHODS: The XIENCE Short DAPT program included 3 prospective, multicenter, single-arm studies enrolling HBR patients who underwent ...

      Known for Bleeding Risk | Eluting Stent | Month Dapt | Hbr Patients | 1 3

      Key People For Heart Failure

      Top KOLs in the world
      John J J V McMurray
      heart failure myocardial infarction atrial fibrillation
      John George Franklin Cleland
      heart failure patients hf atrial fibrillation
      Stephan D Anker
      heart failure iron deficiency cardiac cachexia
      Greegg C Fonarow
      heart failure atrial fibrillation united states
      Karl B Swedberg
      heart failure reduced ejection fraction myocardial infarction
      Piotr P Ponikowski
      heart failure iron deficiency reduced ejection fraction

      Junbo Ge:Expert Impact

      Concepts for whichJunbo Gehas direct influence:Heart failure,  Patients heart failure,  Chronic coronary syndrome,  Aspirin patients,  Placebo patients,  Dapagliflozin placebo,  Rivaroxaban aspirin,  Baseline characteristics.

      Junbo Ge:KOL impact

      Concepts related to the work of other authors for whichfor which Junbo Ge has influence:Heart failure,  Sglt2 inhibitors,  Type 2 diabetes,  Preserved ejection fraction,  Cardiovascular disease,  Patients hf,  Myocardial infarction.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China; Institute of Biomedical Science, Fudan University, Shanghai, China; NHC Key Laboratory of Viral Heart Diseases, Shanghai,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.